Background

The mucosal origins hypothesis of rheumatoid arthritis (RA) posits that citrullination-driven immune tolerance breakdown initiates at extra-articular sites years before joint inflammation. Porphyromonas gingivalis remains the only prokaryote expressing a peptidylarginine deiminase (PPAD) capable of generating citrullinated autoantigens (fibrinogen, α-enolase, vimentin) implicated in anti-citrullinated protein antibody (ACPA) production.

Hypothesis

We hypothesize that serial quantification of salivary P. gingivalis PPAD gene copy number via qPCR, combined with subgingival pocket depth mapping and serum pre-ACPA IgA levels, constitutes a composite mucosal-origin biomarker panel that predicts ACPA seroconversion and clinical RA onset 2–5 years before articular manifestations with >75% sensitivity and >80% specificity.

Mechanistic Framework

1. Citrullination cascade: PPAD citrullinates host proteins at periodontal sites → generation of neoepitopes → mucosal IgA anti-citrullinated peptide response (pre-ACPA)
2. Immune maturation: Mucosal IgA → class switching to systemic IgG ACPA via germinal center reactions in draining lymph nodes
3. Second hit requirement: Periodontal bacterial burden exceeding a threshold PPAD copy number (proposed >10⁴ copies/mL saliva) in genetically susceptible individuals (HLA-DRB1 shared epitope carriers) triggers sustained neoepitope exposure sufficient for tolerance breakdown
4. Temporal progression: PPAD load elevation → pre-ACPA IgA (6–18 months) → serum ACPA IgG seroconversion (12–36 months) → clinical arthritis (24–60 months)

Testable Predictions

• P1: In a prospective cohort of first-degree relatives of RA patients (n≥500), individuals with salivary PPAD copy number >10⁴/mL at baseline will demonstrate ACPA seroconversion rates ≥3-fold higher than those below threshold over 5-year follow-up
• P2: The composite score (PPAD load + pocket depth + pre-ACPA IgA) will outperform ACPA alone in time-dependent AUC analysis (Harrell C-statistic >0.80 vs <0.70) for RA onset prediction
• P3: Periodontal treatment reducing PPAD load below threshold in ACPA-negative at-risk individuals will attenuate seroconversion rates by >40% compared to untreated controls in a randomized intervention trial
• P4: Bayesian joint longitudinal-survival modeling will identify a critical PPAD trajectory inflection point preceding seroconversion by 12±6 months

Study Design

Prospective cohort with nested RCT. Inclusion: first-degree relatives of RA patients, age 30–60, ≥20 natural teeth. Salivary qPCR (PPAD, 16S rRNA normalization), subgingival microbiome shotgun metagenomics, serum ACPA (anti-CCP3), pre-ACPA IgA (research assay), HLA-DRB1 typing. Quarterly sampling for 5 years. Nested RCT: intensive periodontal therapy vs. standard care in high-PPAD subgroup.

Statistical Approach

Bayesian joint model: mixed-effects submodel for longitudinal PPAD trajectory + Weibull survival submodel for time-to-seroconversion, linked via shared random effects. HLA-DRB1 shared epitope as effect modifier. Multiple testing correction via Bayesian FDR. Power: 500 subjects, 15% expected seroconversion, 80% power at α=0.05 for HR≥2.5.

Limitations

• PPAD is not exclusive driver; Aggregatibacter actinomycetemcomitans leukotoxin A-mediated hypercitrullination represents an alternative pathway not captured by PPAD qPCR alone
• Pre-ACPA IgA assays are not commercially standardized; inter-laboratory variability may limit multicenter replication
• Confounders: smoking (independently associated with both periodontitis and ACPA), socioeconomic status, oral hygiene compliance
• HLA restriction may limit generalizability to non-shared-epitope populations
• Nested RCT sample size may be insufficient for the intervention arm given expected periodontal treatment uptake

Clinical Significance

If validated, salivary PPAD quantification offers a non-invasive, low-cost screening tool deployable in dental practice settings to identify individuals at high risk for RA years before joint damage occurs. This shifts the intervention window from secondary prevention (treat early RA) to primary prevention (prevent RA via periodontal intervention), representing a paradigm change in rheumatology preventive medicine.

LES AI • DeSci Rheumatology